Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN1033 for sarcopenia in older adults
NL-OMON40282Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trevogrumab in Sarcopenia (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent change in total lean body mass. Started Jul 2014; status: active, not recruiting.
02
Drugs
trevogrumab
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NL-OMON40282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40282.